Antimicrobial Surveillance Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

FLORHAM PARK, N.J., September 07, 2023--Shionogi Inc., the United States subsidiary of Shionogi & Co., Ltd., (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.), announced the upcoming presentation of new data at IDWeek 2023 (October 11-15, 2023) on its investigational oral antiviral for COVID-19, ensitrelvir (Generic name: ensitrelvir fumaric acid, Code No.: S-217622, hereafter "ensitrelvir"), and Fetroja® (cefiderocol), an antibiotic marketed under the brand name Fetcro

In vitro activity of ceftolozane/tazobactam & comparator agents tested against P. aeruginosa & Enterobacterales isolates from hospitalised patients in Asia.

Element further expands its Life Sciences testing business with additional pharmaceutical and biotech testing capabilities in North America and Europe London, UK – January 14, 2022 – Element Materials Technology (Element) completed its sixth life sciences-focused acquisition of 2021, with the formal...

Element Materials Technology (Element) completed its sixth life sciences-focused acquisition of 2021, with the formal completion of the acquisition of JMI Laboratories (JMI). Element has now built out

Nabriva Publishes Clinical Data Analysis Highlighting Benefits of Outpatient Management of Community Acquired Bacterial Pneumonia (CABP) with Oral XENLETA® (lefamulin) Nabriva Therapeutics US, Inc -Post Hoc analysis published in The Journal of Emergency Medicine demonstrates patients with moderate to severe CABP can be managed effectively as outpatients with a 5-day, monotherapy regimen of oral XENLETA DUBLIN, Ireland, March 16, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative a...